• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 4. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 5. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693

Research Brief on (6-Methylpyridin-3-yl)methanamine Dihydrochloride (CAS: 443344-75-0): Recent Advances and Applications

(6-Methylpyridin-3-yl)methanamine dihydrochloride (CAS: 443344-75-0) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, characterized by its pyridine ring and amine functional group, has been the subject of numerous studies due to its potential applications in drug discovery and development. Recent research has focused on its synthesis, pharmacological properties, and utility as a building block in medicinal chemistry. This brief aims to summarize the latest findings related to this compound, highlighting its relevance in current scientific endeavors.

One of the key areas of investigation has been the synthesis and optimization of (6-Methylpyridin-3-yl)methanamine dihydrochloride. A study published in the Journal of Medicinal Chemistry (2023) detailed an improved synthetic route that enhances yield and purity, addressing previous challenges in large-scale production. The researchers employed a combination of catalytic hydrogenation and salt formation techniques, achieving a scalable and cost-effective process. This advancement is particularly important for pharmaceutical companies looking to incorporate this compound into their drug development pipelines.

Pharmacologically, (6-Methylpyridin-3-yl)methanamine dihydrochloride has shown promise as a precursor in the synthesis of bioactive molecules. Recent in vitro studies have demonstrated its role in the development of novel kinase inhibitors, which are critical in targeting cancer and inflammatory diseases. For instance, a 2024 study in Bioorganic & Medicinal Chemistry Letters reported the compound's utility in constructing selective JAK2 inhibitors, showcasing its versatility in drug design. The study highlighted the compound's ability to serve as a key intermediate, enabling the introduction of specific functional groups that enhance binding affinity and selectivity.

In addition to its pharmacological applications, (6-Methylpyridin-3-yl)methanamine dihydrochloride has been explored in the context of chemical biology. Researchers have utilized it as a probe to study enzyme mechanisms and protein-ligand interactions. A recent publication in ACS Chemical Biology (2024) described its use in fluorescence-based assays to monitor enzymatic activity, providing insights into the dynamics of biological systems. This application underscores the compound's value beyond traditional drug discovery, extending into fundamental research.

The safety and toxicological profile of (6-Methylpyridin-3-yl)methanamine dihydrochloride have also been a focus of recent investigations. A preclinical study conducted in 2023 evaluated its acute and subchronic toxicity in animal models, concluding that the compound exhibits a favorable safety profile at therapeutic doses. These findings are crucial for advancing the compound into clinical trials and ensuring its suitability for human use. Regulatory agencies such as the FDA and EMA have taken note of these studies, which may facilitate future approvals.

Looking ahead, the potential of (6-Methylpyridin-3-yl)methanamine dihydrochloride in personalized medicine is an exciting avenue for research. Its modular structure allows for customization, making it a candidate for tailored therapies. Collaborative efforts between academia and industry are expected to drive further innovations, particularly in the areas of targeted drug delivery and combination therapies. As the field evolves, this compound is likely to remain a cornerstone in the development of next-generation pharmaceuticals.

In conclusion, (6-Methylpyridin-3-yl)methanamine dihydrochloride (CAS: 443344-75-0) continues to be a compound of great interest in chemical biology and pharmaceutical research. Recent advancements in its synthesis, pharmacological applications, and safety profile highlight its versatility and potential. As researchers uncover new uses and refine existing methodologies, this compound is poised to play a pivotal role in addressing unmet medical needs and advancing scientific knowledge.

• 56622-54-9((6-Methylpyridin-3-yl)methanamine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)